Drug, bio-affecting and body treating compositions inventions 01/06

20060019870 - Apoprotein cochleate compositions: Disclosed herein are cochleates and cochleate compositions associated with an apoprotein component and/or a plasmid component that encodes an apoprotein. Also disclosed are methods of making and using the compositions of the invention, including methods of administration. Use of the invention provides safe, effective and efficient delivery of apoproteins and/or...

20060019871 - Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment: The present invention provides for the novel use of a polypeptide related to a fibrinogen γ chain C-terminal fragment or a nucleic acid encoding the polypeptide for inhibiting endothelial cell proliferation. Methods of using the polypeptide or the nucleic acid are provided. Also provided are compositions containing the polypeptide or...

20060019868 - Hemostatic compositions and devices: The present invention includes both sterilized and unsterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid phase, and a discontinuous, biocompatible gaseous phase, each of which...

20060019869 - Intradiscal anti-inflammatory therapy involving autologous adiponectin: Administering an effective amount of APN into an intervertebral disc is disclosed....

20060019873 - Cation complexes of insulin compound conjugates, formulations and uses thereof: either R1 or R2 is is a lower alkyl, optionally including a carbonyl group, and when R1 is a lower alkyl, R2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties...

20060019874 - Cation complexes of insulin compund conjugates, formulation and uses thereof: The invention provides a complex including a cation and an insulin compound conjugate. The insulin compound conjugate includes insulin compound, such as human insulin or an analog thereof, conjugated to a modifying moiety, such as a polyethylene glycol moiety. The invention also includes solids and pharmaceutical compositions including such complexes,...

20060019872 - Oral formulations for poorly absorptive hydrophilic drugs: Disclosed herein is a pharmaceutical composition for oral absorption of polar drugs. The composition consists essentially of (a) at least one polar active substance having a bioavailability of less than 30% which is poorly absorptive through lipid membranes because of its high hydrophilicity and charged ion; (b) at least one...

20060019875 - Autologous coatings for implants: A hydrocephalus shunt having an anti-inflammatory coating applied to at least the outside surface of the ventricular catheter. Such coatings are also applicable to other medical devices or implants....

20060019876 - Targeted delivery of bioaffecting compounds for the treatment of cancer: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis inducing compounds, a method for making such a conjugate, and methods for using the...

20060019877 - Hasylated polypeptides: The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO)....

20060019881 - Human spasmolytic polypeptide in glycosylated form: e

20060019880 - Modulation of synaptogenesis: Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain...

20060019878 - Polynucleotide encoding autoantigens associated with endometriosis: This invention provides a polynucleotide encoding Repro-EN-1.0 and IB1, polypeptides associated with endometriosis. Auto-antibodies against Repro-EN-1.0 and IB1 have been found in subjects diagnosed with endometriosis. This invention also provides methods of using this polynucleotide and polypeptide....

20060019879 - Polynucleotide encoding autoantigens associated with endometriosis: This invention provides a polynucleotide encoding Repro-EN-1.0 and IB1, polypeptides associated with endometriosis. Auto-antibodies against Repro-EN-1.0 and IB1 have been found in subjects diagnosed with endometriosis. This invention also provides methods of using this polynucleotide and polypeptide....

20060019882 - Use of yops as caspase inhibitor: The present invention relates to the use of Yops as caspase inhibitors. More specifically, it relates to the use of YopE and YopT as inhibitors of caspase-1 activity. The inhibitor can be used to treat caspase-1-related pathologies, such as inflammatory diseases and to inhibit caspase-1-related and/or -mediated cell death....

20060019883 - Use of cyclin d1 inhibitors: The present invention relates to use of certain cyclin D1 inhibitors at the manufacture of pharmaceutical preparations to be used in the treatment of patients to improve their response to tamoxifen treatment following a breast cancer treatment, either surgically, using cytotoxic compounds and/or irradiation, as well as a method of...

20060019897 - Anti-angiogenic polypeptides: The invention relates to anti-angiogenic effects of polypeptides derived from fibrinogen....

20060019889 - Anti-osteolytic therapy involving adiponectin: Administering an effective amount of adiponectin into an osteolytic region....

20060019887 - Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer: The present invention relates to compositions and methods for the prevention and/or treatment of bone loss associated with cancer. More particularly, the invention relates to OPG compositions and methods for the prevention and/or treatment of bone loss comprising said compositions. The invention also relates to the use of OPG compositions...

20060019892 - Conopeptides and methods of use: Isolation, synthesis and therapeutic use of compounds and related compositions based on a new class of conopeptides comprising the modified amino acid γ-hydroxyvaline (Hyv=V*). These isolated peptides are the first known example of a naturally occurring polypeptide chain containing Hyv. The active peptides, termed γ-Hydroxyconophans are heavily hydroxylated small peptides....

20060019899 - Epha2 t-cell epitopes and uses therefor: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify...

20060019893 - Factor viia variants: Novel compounds are provided which modulate a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention are variants of Factor VIIa (FVIIa). Pharmaceutical compositions are also provided which...

20060019890 - Method for treating cardiac remodeling following myocardial injury: The invention concerns methods for treating cardiac remodeling in a subject who has undergone myocardial injury, said method comprising the administration of natriuretic peptide to said subject. Preferably the natriuretic peptide is brain natriuretic peptide. The invention also concerns methods for treating structural heart disorders arising from myocardial injury, said...

20060019898 - Methods of treating intestinal ischemia using heparin-binding epidermal growth factor: The present invention provides methods of treating pathologic conditions associated with intestinal ischemia. In the methods, patients at risk for or suffering from intestinal ischemia are treated with a heparin-binding epidermal growth factor product....

20060019885 - Modified bryodin 1 with reduced immunogenicity: The invention relates to the modification of bryodin 1 to result in bryodin 1 proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo. The invention relates furthermore to T-cell epitope peptides derived from said nonmodified protein by means of which it is possible...

20060019895 - Molecular determinants of myeloma bone disease and uses thereof: To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble...

20060019886 - Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone: This invention provides for a protein of the TGF-β superfamily in which the cysteine involved in the normal formation of homodimers is changed to another amino acid. These mutant proteins, as monomers, display higher bone morphogenetic activity than the wild-type protein dimers. Also provided is a method for producing and...

20060019896 - Netrin-related compositions and uses: The present invention provides methods and compositions for modulating proliferation, differentiation, migration, and adhesion of cardiovascular cell types....

20060019888 - Neuregulin based methods and compositions for treating cardiovascular diseases: The present invention relates to compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders in mammals, particularly in humans. More particularly, the present invention provides for compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders using, inter alia, a neuregulin protein, or...

20060019884 - Peptide composition: Provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising...

20060019891 - Protection of cardiac myocardium: The invention provides compositions and methods for protecting vascular tissues from injury that occurs, for example, during occlusion of one or more arteries. In some embodiments, the injury is myocardial infarction. The compositions of the invention include combinations of platelet derived growth factor, vascular endothelial growth factor, and angiopoietin-2....

20060019894 - Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients....

20060019900 - Alpha-4 beta-1 integrin ligands for imaging and therapy: The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3...

20060019901 - Compositions and methods for counteracting effects of reactive oxygen species and free radicals: Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by...

20060019902 - Pth-like peptides: The present invention relates to peptides that are parathyroid hormone (PTH) analogs, useful for the treatment of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, and for stimulating bone repair or favoring the engraftment of a bone implant; to the pharmaceutical compositions comprising these PTH-like peptides and...

20060019903 - Compositions and methods for treating precocious puberty: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and...

20060019904 - Composition for promoting lacrimal secretion: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition comprises a component which activates PAR-2. Also, a contact lens which retains and/or contains said composition for...

20060019905 - Hepatitis c inhibitor peptide analogs: c

20060019906 - Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor: wherein each symbol is as defined in the specification. The present invention also relates to a pharmaceutical composition containing the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; an integrase inhibitor, an antiviral agent, anti-HIV agent, and the like, which contains the 4-oxoquinoline compound or...

20060019907 - Guggulsterone: an inhibitor of nuclear factor - kappab and ikappabalpha kinase activation and uses thereof: The present invention provides an inhibitor of NF-κB, guggulsterone and its analogs. Guggulsterone suppresses NF-κB activation induced by TNF, phorbol ester, okadaic acid, cigarette smoke, H2O2 and IL-1β, as well as constitutive NF-κB activation expressed in most tumor cells. One mechanism by which guggulsterone inhibits activation of NF-κB is through...

20060019908 - Process for the preparation of azithromycin monohydrate isopropanol clathrate: The present invention relates to an improved, cost effective and easy process for the preparation of azithromycin monohydrate isopropanol clathrate. The process provides a one-step method of preparing azithromycin monohydrate isopropanol clathrate directly from 9-deoxo-9a-aza-9a-homoerythromycin A. The process comprises at least partial dissolution and/or suspension of 9-deoxo-9a-aza-9a homoerythromycin A in...

20060019920 - Antisense modulation of mekk4 expression: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided....

20060019912 - Cell transfecting formulations of small interfering rna related compositions and methods of making and use: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions....

20060019911 - Drug-carrier complexes and methods of use thereof: Drug-carrier complexes, drug carriers, pharmaceutical formulations, methods of delivery drugs to an organism or tissue culture, methods of increasing the solubility of a substance, targeted carriers, drug delivery systems and implants are described. The compositions and methods of the invention include forming complexes having reversible associations between nucleotides and drugs....

20060019916 - Immunostimulatory nucleic acids for inducing il-10 responses: The invention relates to methods and products for inducing IL-10 expression using immunostimulatory nucleic acids. In particular, the invention relates to methods and products for inducing IL-10 expression without inducing high levels of IFN-α expression. IL-10-inducing immunostimulatory nucleic acids preferably include a TC dinucleotide at the 5′ end and a...

20060019919 - Immunostimulatory oligonucleotide multimers: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary....

20060019914 - Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes: The presently disclosed subject matter provides DNA molecules designed to down regulate the expression of MMP genes in a cell. Also provided are compositions comprising the DNA molecules. The presently disclosed subject matter further provides methods of using the DNA molecules to inhibit metastasis of a cancer cell. The presently...

20060019915 - Method to modulate the immune system with a novel guanine nucleotide exchange factor: The present invention provides a method of modulating T cell receptor (“TCR”) dependant regulation of a signaling factor in a T cell, and a method of modulating the proliferation and/or differentiation of a T cell, which includes administering to the T cell an IBP modulator in an amount effective to...

20060019923 - Methods and compositions for inducing innate immune responses: The invention relates to TLR ligand formulations that comprise immune stimulating complexes and their use in inducing innate immunity....

20060019910 - Methods for treating and preventing insulin resistance and related disorders: The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and/or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a...

20060019909 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked...

20060019918 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of...

20060019924 - Novel mrna splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy: The present invention relates to novel nucleic acid and protein molecules and their use in neuroblastoma therapy and diagnosis....

20060019921 - Nucleic acid adjuvants: Recombinant nucleic acid molecules are described. The molecules have two nucleic acid sequences, wherein the first nucleic acid sequence is a truncated A subunit coding region obtained or derived from a bacterial ADP-ribosylating exotoxin, and the second nucleic acid sequence is a truncated B subunit coding region. Vectors and compositions...

20060019917 - Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of stromal cell-derived factor-1 (SDF-1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and...

20060019913 - Rna interference mediated inhibtion of protein tyrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression...

20060019922 - Selective killing of cancerous cells: The presently disclosed subject matter provides methods for selectively conferring toxicity on cancerous cells. Also provided are systems and kits that can be employed for performing the disclosed method....

20060019925 - Peritoneal dialysis method: A peritoneal dialysate containing adenosine triphosphate or a salt thereof, and a peritoneal dialysis method using the dialysate. The peritoneal dialysate is safe and causes less peritoneal injuries even when employed in peritoneal dialysis over a long period of time....

20060019926 - Methods for prevention and treatment of mastitis: A method of preventing or treating mastitis in a mammal, involving administering to the mammal a therapeutically effective amount of diethylaminoethyl-dextran (DEAE-dextran) or dextran....

20060019927 - Anti-viral uses of borinic acid complexes: Compositions and methods of use of borinic acid complexes, especially hydroxyquinoline, imidazole and picolinic acid derivatives, as anti-viral agents as well as therapeutic agents for the treatment of diseases caused by viruses are described....

20060019928 - Tricyclic-heteroaryl compounds useful as kinase inhibitors: m

20060019929 - Combination therapies employing platelet aggregation drugs: The present invention provides pharmaceutical compositions comprising a platelet aggregation inhibitor and a compound selected from pyridoxal-5′-phosphate, a pyridoxal-5′-phosphate related compound, or a pharmaceutically acceptable salt thereof. The invention also includes methods for using a platelet aggregation inhibitor and a compound selected from pyridoxal-5′-phosphate, a pyridoxal-5′-phosphate related compound, or a...

20060019930 - Treatment and prevention of tissue damage: An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of...

20060019931 - Treating bone-related disorders with selective androgen receptor modulators: This invention provides method of treating, preventing, suppressing, inhibiting, or reducing the risk of developing a bone-related disorder, for example osteoporosis, osteopenia, increased bone resorption, bone fracture, bone frailty and/or loss of bone mineral density (BMD), by administering a therapeutically effective amount of a selective androgen receptor modulator (SARM) and/or...

20060019932 - Treatment of rheumatoid arthritis by inhibition of pde4: A method of treatment of rheumatoid arthritis administers an effective amount of a compound that inhibits phospho-diesterase-4....

20060019933 - Process for preparing stabilized vitamin d: This invention is related to a process for preparing a stabilized form of vitamin D which comprises the steps of: a) dissolving vitamin D in a solution that contains water and at least one surfactant to produce a mixture; b) spraying the mixture onto an inert carrier to produce a...

20060019934 - Anti-hiv-1 activity of betulinol derivatives: R2 is —H, —CH3, —CHO, —CH2OH, —CH2OCH3, —CH2OC(O)CH3, —COCH3, or —COOH, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell. A method of treating HIV-1 infection in a subject is also disclosed. This method involves administering a therapeutically effective amount of...

20060019935 - Composition and method for treating acne including anti-inflammatory hepes oleate: The present invention is directed toward a topical composition for the treatment of acne comprising water, an anti-acne agent such as benzoyl peroxide, thickening agent, emulsifiers, stabilizers, and a natural esterified anti-inflammatory (Hepes Oleate). This combined therapy is more effective than either active ingredient alone and is particularly effective for...

20060019936 - Methods and compositions for treating cancer: The invention provides compounds and methods for treating cancer. Exemplary compounds are multi-functional compounds with two different moieties connected by a linker. Compounds of the invention can activate one or more pathways that result in the inhibition of cell growth. The invention includes cytostatic and cytotoxic compounds. Methods and compositions...

20060019937 - Novel crystalline forms of 6alpha, 9alpha -difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxy-androsta-1,4-diene 17beta-carboxylic acid and processes for preparation thereof: Novel crystalline forms II, III, IV, V, VI, VII and VIII of 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxyandrosta-1,4-diene-17β-carboxylic acid, a chemical intermediate useful in the preparation of fluticasone propionate, and novel methods of making these forms, substantially free of water, are disclosed....

20060019938 - Estrogen administration for treating male cognitive dysfunction or improving male cognitive function: Disclosed are methods of treating a male subject diagnosed with cognitive dysfunction that include administering an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof, to the male subject. Also disclosed is a method of improving cognitive function in a hypogonadal male subject that includes transdermally administering to the...

20060019939 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase...

20060019941 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase...

20060019940 - Novel benzoxazocines and their therapeutic use: Compounds of the general formula (1), wherein one of W, X, Y and Z is N or CR4 and the others are each CH; and R4 is a specified substituent. These compounds inhibit monocamine reuptake, and are useful in the treatment of pain, emesis depression, post traumatic stress disorders, attention...

20060019942 - Metal complex glycogen synthase kinase 3 inhibitors: The present inventive subject matter relates to novel metal complex glycogen synthase kinase 3 inhibitors, methods for making such compounds, and methods for using such compounds for treating diseases and disorders mediated by glycogen synthase kinase 3 activity....

20060019944 - Cyclopentylamine and cyclohexylamine derivatives as nk-1/ssri antagonists: e

20060019943 - Homopiperidine derivatives as nk-1 antagonists:

20060019945 - Granzyme b inhibitors: The present invention encompasses compounds of Formula (I) and pharmaceutically acceptable salts or hydrates thereof. The compounds are inhibitors of granzyme B and are useful for treating autoimmune and chronic inflammatory diseases. Pharmaceutical compositions and methods of use are also included....

20060019946 - 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1h)-one: e

20060019947 - Therapeutic chromone compounds: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation,...

20060019948 - Methylidene-d-xylopyranosyl- and oxo-d-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture: o

20060019949 - Benzothiazole derivatives: R4 is lower alkyl; hetaryl is 3H-imidazole-2,4-diyl or 1H-pyrazole-1,4-diyl; n is 1 or 2; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. These compounds may be used for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression,...

20060019950 - Benzathiazol-acetamides: R1 is cycloalkyl, substituted by OR or is 2-(7-oxa-bicyclo[2.2.1]hept-1-yl)-ethyl; R is hydrogen, lower alkyl or C(O)-lower alkyl; X is —CHR′—; and R′ is hydrogen or lower alkyl; and pharmaceutically acceptable acid addition salts, optically pure enantiomeres, racemates or diastereomeric mixtures thereof for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's...

20060019952 - Anti-viral therapeutics: Heterocyclic compounds of formula (I), (II), (III), and (IV) and methods of treating or preventing an HIV-mediated disorder by administering a compound of formula (I), (II), (III), or (IV) are described herein....

20060019953 - Pyridine inhibitors of erk2 and uses thereof: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders....

20060019951 - Vacuolins: The present invention provides compositions and methods relating to vacuolins and their uses. Vacuolins are small molecule agents that affect certain membrane fusion events involving intracellular compartments. The invention further provides compositions and methods for altering antigen presentation mediated by class II MHC molecules, and/or for inhibiting histamine release from...

20060019954 - Method for reducing the likelihood of the occurrence of cardiac arrhythmias: A method is described for reducing the likelihood of the occurrence of a cardiac arrhythmias of the type leading to sudden cardiac death in a mammalian subject. The method comprises administering to the mammalian subject an effective amount of a composition to agonize β3 adrenergic receptors in the mammalian subject....

20060019955 - Oculoselective drugs and prodrugs: m

20060019956 - Compositions useful as inhibitors of rock and other protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders....

20060019957 - Imidazotriazines as protein kinase inhibitors: e

20060019960 - Antitumoral analogs of et-743: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene...

20060019961 - Estrogen receptor ligands: The present invention relates to estrogen receptor ligands, and compounds and methods for treating diseases associated with excessive estrogen receptor activity....

20060019958 - Immunity-related protein kinase inhibitors: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring...

20060019959 - Novel quinoxalinone derivatives: e

20060019962 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases....

20060019963 - Compounds: This invention relates to a method for selecting PDE IV inhibitors which have a salutory therapeutic index, and to compounds having these properties....

20060019964 - Compounds: i

20060019965 - Gonadotropin releasing hormone receptor antagonists: The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists....

20060019966 - Method for treating nervous system disorders and conditions: The present invention is directed to selective dopamine reuptake inhibitors, including (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (−)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS), chronic pain, and Shy Drager syndrome....

20060019967 - Sars cov main protease inhibitors: e

20060019970 - Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites: The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone....

20060019969 - Use of compounds active on the sigma receptor for the treatment of allodynia: The present invention refers to the use of compounds active on the sigma receptor for the treatment of allodynia....

20060019968 - Use of compounds active on the sigma receptor for the treatment of neuropathic pain: The present invention refers to the use of compounds active on the sigma receptor for the treatment of neuropathic pain, especially certain subtypes of neuropathic pain....

20060019971 - Treatment of cardiovascular disease with inhibitors of p38 kinase: The present invention concerns methods of treatment for acute coronary syndrome using a pharmaceutically effective amount of an inhibitor of p38 MAP kinase. More specifically, the invention concerns the treatment of cardiovascular disorders associated with atherosclerosis....

20060019972 - Methods of treating cancer by inhibiting histone gene expression: Methods are provided for decreasing the rate or inhibiting neoplastic cell proliferation by reducing or inhibiting histone H4 gene expression or histone H4 activity. Also provided are methods of treating a patient with a neoplastic disease, and compositions useful for treating a cancer patient, including, for example, a composition containing...

20060019973 - Quinolin-,isoquinolin-,and quinazolin-oxyalkylamides and their use as fungicides: Fungicidal compounds of the general formula (1) wherein one of X and Y is N or N-oxide and the other is CR or both of X and Y are N....

20060019974 - 4-amino-quinazolines: Quinazolines of the formula (I) in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein IbIX antagonists....

20060019975 - Novel piperidyl derivatives of quinazoline and isoquinoline: The invention pertains to new piperidyl-substituted quinazoline and isoquinoline derivatives that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such...

20060019976 - Methods for treating hepatitis c: In accordance with the present invention, compounds that can inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of...

20060019978 - Spirocyclic compounds useful as modulators of nuclear hormone receptor function: Spirocyclic compounds, methods of using such spirocyclic compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed....

20060019977 - Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient: (wherein R1 is H, alkyl, alkenyl, etc.; R2 is keto, thioketo, alkyl, etc.; R3 is alkyl, alkenyl, etc.; AB ring is fused bi-cyclic ring or spiro ring), quaternary ammonium salts thereof, N-oxides thereof, non-toxic salts thereof, or pharmaceutical compositions comprising them, as an active ingredient. The compounds of the formula...

20060019979 - Method for the selective preparation of 3-oxo-4-aza-5a androstane compound: This invention relates to a method for selectively preparing the 3-oxo-4-aza-5¥á-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in the presence of zinc....

20060019980 - Methods for treating or preventing erectile dysfunction or urinary incontinence: The present invention relates to methods for treating or preventing erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a compound of the invention....

20060019981 - Method of preparing inhibitors phosphodiesterase-4: In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula (V), which are useful in making inhibitors of phosphodiesterase-4: The present invention is also directed to a method of preparing phosphodiesterase inhibitors comprising the Formula (IX, IXa)...

20060019982 - Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV...

20060019983 - Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV...

20060019984 - Treatment of diseases with alpha-7nach receptor full agonists: The present invention relates to compositions and methods to treat diseases or conditions with alpha-7 nicotinic acetylcholine receptor (AChR) full agonists by decreasing levels of tumor necrosis factor-alpha and/or by stimulating vascular angiogenesis....

20060019986 - (r/s) rifamycin derivatives, their preparations and pharmaceutical compositions: or its salts, hydrates or prodrugs thereof; wherein a preferred R1 comprises hydrogen or acetyl and a prefered R2 comprises hydrogen, methyl or other lower alkyls; wherein asterik (*) denotes the carbon bearing the chiral center, wherein absolute configuration is assigned as R or S. Methods of preparation of the...

20060019985 - Rifamycin derivatives: wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes....

20060019987 - Methods and compositions for inhibiting, destroying, and/or inactivating viruses: The present disclosure provides compositions, methods, and processes for the inhibiting, destroying, and/or inactivating viral contaminants in a biological source material, or treatment of viral infections. The disclosed compositions include one or more quaternary ammonium compounds. One exemplary method includes contacting the biological source material with a solution containing one...

20060019988 - Compounds, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed....

20060019989 - Compositions comprising 5-alpha reductase inhibitors and serms and methods of use thereof: This invention provides for combinations of 5 alpha reductase inhibitors and SERMs. These combinations are useful in: 1) preventing prostate carcinogenesis in a subject; 2) preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis in a subject; 3) treating a subject with prostate cancer; 4) suppressing,...

20060019990 - Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy....

20060019991 - Diaryl ether beta2 adrenergic receptor agonists: The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds....

20060019993 - 1-amido-3-(2-hydroxyphenoxy)-2-propanol derivatives and a process for preparing 2-amidomethyl-1,4-benzodioxane derivatives: wherein cycle A may have further 1 to 4 substituents, and said substituent means a substituent selected from the group consisting of saturated or unsaturated C1-4 alkyl group, aralkyl group in which alkyl moiety has 1 to 4 carbon atoms, aryl group, halogen atom, halogenated C1-4 alkyl group, C2-5 alkanoyl...

20060019992 - Cycloalkylamine derivatives as nk-1/ssri antagonists: e

20060019994 - I-sulphonlyl piperidine derivatives: Piperidine derivatives of formula (1) that are useful in the inhibition of metalloproteinases, in particular TNF-α Converting Enzyme (TACE) and thus in the treatment of autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy....

20060019995 - 2,3-dihydro-4(1h)-pyridone derivatives , method for production thereof and pharmaceutical composition comprising the same: R3 represents hydrogen, linear or branched (C1-C6)alkyl optionally substituted by one or more identical or different groups selected from hydroxy, amino and linear or branched (C1-C6)alkoxy, Ar represents aryl or heteroaryl, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same...

20060019996 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto: wherein A, R1, R2, R3a, R3b, R4, R5, R6 R7 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof...

20060019997 - Triazole compounds and their use as metabotropic glutamate receptor antagonists: wherein P, Q, X1, X2, X3, X4 X7, X8, R1, R2, R3, m, n, and p are as defined as in formula I, or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of...

20060019998 - Histamine-3 receptor antagonist: as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound...

20060019999 - Novel compounds: There are provided novel compounds of formula (I) wherein R1, R2, R3, R10, M, Q, T, U, Y, V and W are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors...

20060020000 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective...

20060020001 - Use of cathepsin k inhibitors for the treatment of glaucoma: Compositions containing inhibitors of cathepsin K (CTSK) expression and/or activity are provided. Methods for the treatment of glaucoma using the compositions of the invention are further provided....

20060020002 - Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds....

20060020003 - Biphenyloxy-acids: The present invention relates generally to substituted biphenyloxy acids (such as 4′-aryl-amido-biphenyl-4(3)-yloxy-acids and 4′-aryl-amidomethyl-biphenyl-4(3)-yloxy-acids) and methods of using them....

20060020004 - Isoxazolidine compounds for treatment of bacterial infections: The present invention relates to antibiotic compounds and intermediates useful in their preparation. Many of the antibiotic compounds contain a substituted isoxazolidine ring. The invention also relates to pharmaceutical compositions containing a compound of the invention. The invention further provides processes for the preparation of compounds of the invention, and...

20060020005 - Process for preparing losartan: A process for preparing losartan, comprising reacting trityl losartan with an aqueous acid....

20060020006 - Substituted triazoles as sodium channel blockers: Substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or...

20060020007 - Compositions containing policosanol and biotin and their pharmaceutical uses: A composition is provided which contains policosanol and biotin and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance,...

20060020008 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed....

20060020009 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors: m

20060020010 - Substituted pyrazoline compounds, their preparation and use as medicaments: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals....

20060020011 - Arylpyrrolidine derivatives as nk-1 /ssri antagonists: e

20060020013 - Control of arthropods in animals: A method of controlling parasites in or on an animal comprising administering to the animal a parasiticidally effective, substantially non-emetic 1-arylpyrazole....

20060020012 - Pyrazole derivatives: or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse...

20060020014 - Method for treating nervous system disorders and conditions: The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain....

20060020015 - Method for treating nervous system disorders and conditions: The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain....

20060020016 - Processes and intermediates: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof....

20060020017 - Use of serotonergic compound for a method of treatment of hot flushes in post-menopausal women: The present invention relates to a method of treatment of hot flushes with a 5-HT2C receptor agonist and in particular to the use of the selective 5-HT2C receptor agonists 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine and (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy-pyrrolidine or pharmaceutically acceptable acid addition salts thereof for the manufacture of a pharmaceutical formulation adapted for the treatment...

20060020018 - Novel spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors: The present invention is directed to novel spiro-benzo[C]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes,...

20060020019 - Aryloxyalkylamine nk-1/ssri inhibitors: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both....

20060020020 - Regulators of the hedgehog pathway, compositions and uses related thereto: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a...

20060020022 - Enantioselective separation method: This invention relates to a method for separating enantiomers of a substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-1,2-dihydro-quinoline-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-2H-thiochromene-3-carboxylic acid or ester, a substituted 3-trifluoromethyl-3,4-dihydro-naphthalene-2-carboxylic acid or ester, or a pharmaceutically acceptable salt of the acids or esters, using enantioselective fractional crystallization, enantioselective high...

20060020023 - Racemization method: This invention relates to a method for racemizing enantiomers of a substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-1,2-dihydro-quinoline-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-2H-thiochromene-3-carboxylic acid or ester, or a pharmaceutically acceptable salt of the acids or esters, using secondary amines, and optionally hydroxides, alkoxides, or sulfites at reaction mixture...

20060020021 - Use of compounds derived from 2,3-dehydronaringenin for the treatment of inflammatory processes and pharmaceutical composition containing said derivatives: The present invention refers to the use of 2,3-dehydronarinegenin (apigenin) derivatives of Formula (I) for the treatment or prophylaxis of inflammatory processes and chronic diseases derived from inflammatory processes, as well as to a pharmaceutical composition containing them, together with excipients....

20060020024 - Tnp-470 species, polymer conjugates and use thereof: The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular...

20060020025 - Method of treating acne vulgaris and rosacea with carbamide peroxide: A method of treating inflammatory acne vulgaris or inflammatory acne rosacea comprises the topical application of a formulation incorporating carbamide peroxide in a pharmaceutically acceptable vehicle. Inflammatory acneform lesions that can be successfully treat with the inventive method include erythematous papules, pustules, nodules, and cysts. Suitable pharmaceutical vehicles for the...

20060020026 - Ferric organic compounds, uses thereof and methods of making same: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with...

20060020027 - Use of curcumanoids as histone acetyltransferases (hats) inhibitors: e

20060020028 - Levodopa prodrugs, and compositions and uses thereof: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed....

20060020029 - Pharmaceutical compositions from ethnobotanicals: This invention relates to the field of drug discovery. Specifically, it describes a method (“Inverted Drug Screening” or “IDS™”) of identifying therapeutics from ethnobotanical (EB) preparations by repeatedly fractionating and testing fractions from EB sources. One aspect of the invention relates to quinic acid derivatives (e.g., derivatives of 3,5-dicaffeoyl quinic...

20060020030 - Enhanced purity trans-lutein-ester compositions and methods of making same: The present invention relates a composition having a high content of xanthophyll esters, where the xanthophyll ester component of the composition is comprised of a high proportion of trans-lutein esters. The present invention also provides methods of making and using such a composition....

20060020031 - Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses: A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration,...

20060020032 - Animal composition: The present invention relates to a composition which delivers an amount of leucine sufficient to enhance the learning ability of an animal. The present invention also relates to a food supplement for enhancing the learning ability of an animal and to methods for enhancing such learning ability....

20060020033 - Method for treating dermatological viral infections: A method for treating dermatological viral infections includes applying a photosensitizing agent to virally infected skin, allowing the virally infected skin to become photosensitive, and illuminating a beam of visible light onto the photosensitive skin to produce a photodynamic reaction substantially reducing the amount of viral infection to the skin....

20060020034 - Processes for the preparation of gabapentin: The present invention relates to new processes for the preparation of gabapentin by the desilylation of a silylated gabapentin or by the silylation-desilylation of an acid addition salt of gabapentin with a silylating agent....

20060020035 - Bone marrow protection with n-acetyl-l-cysteine: The present invention provides methods for preventing or ameliorating chemotherapeutic agent-induced bone marrow toxicity. These methods comprise administering an effective amount of N-acetyl-L-cysteine (L-NAC), alone or in combination with other agents, to a subject in need thereof. The present invention also provides compositions for preventing or ameliorating chemotherapeutic agent-induced bone...

20060020036 - Methods and compositions to promote bone homestasis: The present invention relates to a method for promoting osteogenesis by contacting osteoblast progenitor cells with an LXR agonist. Said method is useful for the treatment or prevention of an imbalance in bone homeostasis in a subject using bone homeostasis-promoting compositions comprising an effective osteogenic stimulating amount of an LXR...

20060020037 - Tazarotenic acid and esters thereof for treating autism: This invention provides a method of treating autism comprising administering a therapeutically effective amount of a compound selected from the group consisting of tazarotenic acid, or ester or salt, thereof, to a person in need of such treatment. Preferably said compound is tazarotene....

20060020038 - Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease: i

20060020039 - Benzamides and related inhibitors of factor xa: Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....

20060020041 - Anti tubercular drug: compositions and methods: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis....

20060020040 - Bupropion hydrochloride solid dosage forms: The present invention relates to solid dosage forms that contain bupropion hydrochloride and glucono delta lactone or its corresponding open chain hydroxy acid derivative. The bupropion hydrochloride retains at least 80% of the bupropion hydrochloride potency after storage for three months at 40° C. and 75% relative humidity. The solid...

20060020042 - Memantine for the treatment of mild and mild to moderate alzheimer's disease: The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain...

20060020043 - Methods and compositions for reducing c-reactive protein: The present invention provides methods for the treatment and/or amelioration of inflammation in a subject, including humans, by administering to a subject a therapeutically effective amount of a biologically active mixture of high purity, high molecular weight straight chain primary aliphatic alcohols (referred to collectively herein as policosanol). Also included...

20060020045 - Methods and compositions for treating inflammatory disorders of the gastrointestinal tract: The present invention provides compositions and methods for treating or preventing the development of inflammatory disorder of the gastrointestinal tract in a subject, comprising administering to a subject therapeutically effective amount of a biologically active mixture of high purity, high molecular weight straight chain primary aliphatic alcohols (referred to collectively...

20060020044 - Methods and compositions for treating or preventing macular-degeneration related disorders: The present invention provides methods for treating or preventing the development of macular degeneration-related disorders in a subject, including humans by administering to a subject therapeutically effective amount of a biologically active mixture of high purity, high molecular weight straight chain primary aliphatic alcohols (referred to collectively herein as policosanol)....

20060020046 - Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies: The invention is concerned with the use of lycopene, optionally in combination with vitamin E and/or C or other biologically active ingredients as disclosed in the specification, in the manufacture of a composition for the primary and secondary prevention of angiogenesis-associated pathologies and coadjuvant treatment thereof; as well as with...

20060014668 - Antigenic gp 100 compounds for therapy and diagnosis and methods of using same: The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of gp 100-related cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of cancer antigens associated with gp 100 related cancers and malignancies....

20060014669 - Method for treating cancer and increasing hematocrit levels: The present invention provides a method for inhibiting undesired angiogenesis including tumor-associated angiogenesis. The invention further provides a method for increasing the number of red blood cells or hematocrit in the circulation in subjects in need thereof. The invention also provides a method for simultaneously treating low hematocrit and undesired...

20060014667 - Peptide composition and method for delivering substances into the cytosol of cells: Weak-base amphiphilic delivery peptide compositions are described for use in delivering large polar substances (cargo) into the cytosol of animal cells via an indirect endocytosis-mediated delivery process. The delivery peptides, which are predominantly non-ionic at neutral pH, bind but do not permeabilize cell membranes. After endocytosis of both delivery peptides...

20060014666 - Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders: The present invention relates to an active targeted water-solubility macromolecule polymer, conjugate With interferon and pharmaceutical composition comprising the conjugate. The targeted agent includes, for example, glucose, galatose and the like, as well as their derivates. The conjugate of the present invention is well in water-solubility and havc long physiological...

20060014665 - Therapeutic agent: The invention relates to an agent for the depletion of unwanted proteins from plasma comprising a plurality of ligands covalently co-linked to produce a complex with a plurality of proteins wherein at least two of the ligands are capable of being bound by ligand binding sites on the proteins and...

20060014670 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia: Pharmaceutical compositions comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia....

20060014671 - Stabilized hemoglobin solutions: A hemoglobin solution packaged in a flexible oxygen-impermeable container system. The container system includes a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer. The flexible container system further includes an interface port for filling the flexible container with the...

20060014673 - Kappa-a conopeptides and uses therefor: The present invention is directed to kappaA (κA) conopeptides and the use of these peptides for blocking the flow of potassium ions through voltage-gated potassium channels. The κA conopeptides include unglycosylated and O-glycosylated peptides....

20060014672 - Tumor specific oligosaccharide epitopes and use thereof: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of...

20060014676 - Cyclic peptides for treatment of cachexia: e

20060014675 - Methods for preparing internally constrained peptides and peptidomimetics: The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region and a method of stabilizing an alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region within a peptide structure. The resulting peptides and methods of using them are also disclosed....

20060014674 - Methods for preparing purified lipopeptides: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against...

20060014677 - Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds: The invention provides methods for predicting toxicity related to calcineurin inhibition therapy by measuring the peak concentration of drug and the trough concentration of the drug, calculating a peak-trough fluctuation, and comparing this peak-trough fluctuation to known values to predict if the patient will exhibit calcineurin-inhibition therapy-related toxicity. The invention...

20060014687 - Bone delivery conjugates and method of using same to target proteins to bone: A bone delivery conjugate having a structure selected from the group consisting of: A) X-Dn-Y-protein-Z; and B) Z-protein-Y-Dn-X, wherein X is absent or is an amino acid sequence of at least one amino acid; Y is absent or is an amino acid sequence of at least one amino acid; Z...

20060014682 - Cxcr4 antagonist treatment of hematopoietic cells: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal....

20060014686 - Diagnoses and therapeutics for cancer: Methods and compositions for treating and diagnosing cancer and screening for agents for such treatment and diagnosis are provided. The methods involve screening for agents that modulate the activity or expression of FOXM1, which has been discovered herein to play a role in cell growth and cell cycle regulation. Methods...

20060014690 - Epidermal growth factor receptor antagonists and methods of use: The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity...

20060014685 - Glucagon-like peptide-1 analogs with long duration of action: Novel GLP-1 analogs having improved biological potency as well as extended pharmacological activity are described herein. More specifically, the present invention relates to GLP-1 analogs (28 or 29 aa long) comprising amino acid substitutions at one or more of the following positions: 8, 20, 27, 30 and 33....

20060014683 - Inactivation resistant factor viii: The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid...

20060014679 - Insulin resistance improving agents: A compound or its salt inhibiting the activity of a protein having an amino acid sequence which is the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, an extracellular domain of the protein above, an antibody, an antisense polynucleotide,...

20060014691 - Mechanically activated channel blocker: The present invention discloses a peptide of SEQ ID NO:1 and its variants that blocks stretch-activated ion channels. All amino acids in this peptide are D-amino acids. The peptide, designated as D-GsMTx4, is an enantiomer of a peptide GsMTX-4 present in the venom of the spider Grammostola spatulata. The present...

20060014689 - Method of treatment of cancer using guanosine 3', 5' cyclic monophosphate (cyclic gmp): A method of treating cancer through use of guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 μM), 84% (1 mM), 31% (1 μM), and 30% (1 μM), respectively....

20060014688 - Methods of inhibiting tumor cell proliferation: The invention provides methods for inhibiting tumor cell proliferation by inhibiting FoxM1B activity, expression, or nuclear localization in a tumor cell. The invention also provides methods for preventing tumor progression in an animal comprising inhibiting FoxM1B activity, expression, or nuclear localization. Furthermore, the invention provides methods for inhibiting tumor cell...

20060014692 - Methods of using non-human animal apoliprotein a-i protein: The invention provides methods and compositions for treating disorders using non-human animal Apolipoprotein A-I (ApoA-I) protein. The invention provides methods and compositions for treating disorders in animals, including humans, associated with dyslipidemia, including hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, HDL deficiency, ApoA-I deficiency, cardiovascular disease, atherosclerosis, restenosis, and other disorders such as...

20060014678 - Modification of feeding behavior: Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject....

20060014684 - Novel uses of egf: This invention relates to treating or preventing pathogenic infections with an epidermal growth factor (EGF). EGF is capable of inhibiting pathogenic colonization of pathogens in a variety of tissue or cell types. Since pathogenic colonization is essential for pathogenic infection, EGF can be used as an effective preventive and therapeutic...

20060014680 - Peptides and compounds that bind to the il-5 receptor: New IL-5 receptor antagonists and methods of use are described, e.g., in the treatment of IL-5 receptor mediated disorders. The compounds include both monomers and dimers that were identified using one or more of alanine scans, lysine scans, other residue substitutions, and C- and N-terminal truncations and additions vis a...

20060014681 - Three-dimensional structure of complement receptor type 2 and uses thereof: Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural...

20060014693 - Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity: A novel peptide, derived from the human fibroblast growth factor (bFGF), is identified. Said molecule is able to inhibit in vitro the effects of Platelet Derived Growth Factor (PDGF-BB) and basic Fibroblast Growth Factor (bFGF) on primary rat smooth muscle cells (RASMC) and primary bovine endothelial cells (BAEC). Said molecule...

20060014694 - Peptide purification: A nona- or decapeptide is purified from residual organic solvent by dissolving in a solvent comprising water and at least one C1-C3 alcohol followed by precipitation into a vigorously stirred solvent consisting of an alkyl ester of a carboxylic acid, the ester comprising from 3 to 6 carbon atoms, and...

20060014695 - Hpma-polyamine conjugates and uses therefore: The inventions provide compositions and methods for nucleic acid delivery comprising IIPMA conjugated to a polyamine. These compositions have the benefit of the steric hindrance of HPMA and the nucleic acid binding capability of a polyamine. Useful polyamines for this purpose include spermine, spermidine and their analogues, and DFMO. These...

20060014696 - Modulators of beta-amyloid peptide aggregation comprising d-amino acids: Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected...

20060014697 - Pharmaceutical compositions for prevention of overdose or abuse: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that...

20060014698 - Nebulized pharmaceutical compositions for the treatment of bronchial disorders: The present invention provides methods and pharmaceutical compositions for the treatment of bronchial disorders by inhalation therapy. In various embodiments, the active ingredient of the pharmaceutical compositions is one or more of a sulfated pentasaccharide and a peptidomemtic of a tripeptide. In various embodiments, the active ingredient of the pharmaceutical...

20060014699 - Aqueous pharmaceutical formulaton comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism: An aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC—CH2—(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof, a process for the preparation of such a pharmaceutical formulation, the use of such a formulation in the treatment of thromboembolism as well as a method of treating a patient in need of antithrombotic treatment...

20060014700 - Inhibitors of iap:

20060014701 - Novel amide derivatives as growth hormone secretagogues: wherein n is an integer from 0-4, R4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, R5 and R6 are independently selected from hydrogen, substituted or unsubstituted alkyl, or R5 and R6 or R4 and R5 are taken together to form substituted or unsubstituted...

20060014702 - Antimicrobial agent: The present invention relates to novel thioglycosides of D-galactofuranose that have an antimicrobial action, methods for their synthesis, pharmaceutical compositions containing them and methods for the treatment of patients suffering microbial infection....

20060014703 - Antimicrobial quaternary surfactants based upon alkyl polyglycoside: The invention relates to a series of polyglycoside derivatives that contain water-soluble cationic groups introduced into the molecule by reaction with the hydroxyl groups present in the starting polyglycoside molecule, with an chloro hydroxy propyl containing cationic material. The materials are multifunctional, providing not only wetting, and conditioning, but also...

20060014704 -